Immediate Rheumatology Referral and Comprehensive Serologic Workup
This 56-year-old woman with 6 months of bilateral arm and hand pain, family history of RA, and bothersome symptoms severe enough to prompt ER visit requires urgent rheumatology referral within 6 weeks and should not be reassured by a single negative CRP. 1
Why the Negative CRP Doesn't Rule Out Inflammatory Arthritis
A normal CRP occurs in more than 40% of RA patients at presentation 2. This is a critical pitfall—many clinicians incorrectly assume normal inflammatory markers exclude inflammatory arthritis. The negative CRP in this case should not delay evaluation or treatment decisions. Additionally:
- About one-third of RA patients are seronegative (RF and anti-CCP negative) 2
- Some patients have "rampant clinical and laboratory abnormalities despite an apparent lack of radiographically detectable rheumatoid arthritis" 3
- Patient-reported functional difficulties are abnormal in 89% of RA patients at presentation, making them more sensitive than ESR or CRP 2
Immediate Evaluation Steps
Clinical Examination Priority
Perform a detailed joint examination looking specifically for:
- Swelling in metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints bilaterally
- Morning stiffness duration (>30-60 minutes suggests inflammatory)
- Tender and swollen joint counts
- Pattern of joint involvement (symmetric polyarthritis is classic but not universal) 1
Clinical examination is the method of choice for detecting arthritis, which may be confirmed by ultrasonography 1. Ultrasound can detect synovitis not apparent on physical exam.
Complete Serologic Panel Required
Order the following immediately:
- Rheumatoid factor (RF)
- Anti-citrullinated protein antibodies (anti-CCP/ACPA) - highly specific for RA
- ESR (may be elevated even when CRP is normal)
- Repeat CRP
- ANA (antinuclear antibodies)
- Complete blood count
- Comprehensive metabolic panel
The anti-CCP antibody is particularly valuable as it can be positive in seronegative RA presentations 4 and has high specificity for RA.
Imaging Strategy
- Plain radiographs of hands and feet to assess for erosive changes, though absence of radiographic changes does not exclude RA 3
- If radiographs are negative but clinical suspicion remains high, proceed to MRI or ultrasound of hands, which are far more sensitive for detecting early synovitis and erosions 3
Risk Stratification for Persistent/Erosive Disease
Even if she doesn't meet full RA classification criteria yet (early undifferentiated arthritis), assess these risk factors for persistent and erosive disease 1:
- Number of swollen joints
- Acute phase reactants (ESR, even if CRP normal)
- RF and anti-CCP positivity
- Imaging findings (ultrasound or MRI synovitis)
- Family history of RA (present in this case)
Treatment Threshold
If risk factors for persistent arthritis are present, start DMARDs within 3 months of symptom onset, even without meeting full RA classification criteria 1. Given this patient already has 6 months of symptoms, she is past the optimal treatment window.
Methotrexate is the anchor drug and should be part of first-line therapy unless contraindicated 1.
For immediate symptom relief while awaiting rheumatology:
- Short-term low-dose prednisone (<6 months, lowest effective dose) can be considered 1
- NSAIDs at minimum effective dose for shortest duration after assessing GI/renal/CV risk 1
Critical Differential Considerations
Given the family history and presentation, also consider:
- Polymyalgia rheumatica (though typically age >50, more proximal symptoms)
- Psoriatic arthritis (can affect DIPs, check for psoriasis/nail changes)
- Inflammatory myopathies including dermatomyositis with arthritis (check for muscle weakness, rash, consider anti-Mi-2, anti-Jo-1 antibodies if atypical features) 5
- Osteoarthritis with inflammatory flares (less likely given bilateral symmetric pattern and severity)
Key Pitfalls to Avoid
- Do not be falsely reassured by normal CRP alone - it's normal in >40% of early RA 2
- Do not wait for radiographic erosions - they may not appear for months to years despite active disease 3
- Do not delay DMARD therapy if risk factors present - the 6-month symptom duration already represents delayed care 1
- Do not dismiss seronegative results - one-third of RA is seronegative 2
The goal is to achieve clinical remission and prevent irreversible joint damage, work disability, and mortality - outcomes that correlate more strongly with functional status than with laboratory values 2. Early aggressive treatment within 3 months of symptom onset prevents these poor outcomes 1.